. 2014 Sep 2;2(3):654–685. doi: 10.3390/vaccines2030654

Table 6.

Cytokine-adjuvanted Schistosoma vaccine candidates classified as a function of the adjuvant.

Adjuvant	Administration	Antigen ^a	Reduction (%) ^b		References
Adjuvant	Administration	Antigen ^a	Eggs	Worms	References
IL-12 plasmid adjuvant	i.m	Sj23	22–28	27–35	[24,25]
	i.m	SjTPI	44–53	30–33	[24,25]
	i.m	SjTPI ^c	13–60	21–53	[21,57]
	i.m	SjTPI (native)	47–53 (pig)	48–53	[21,57]
	?	SjTPI	18	32	[21]
	?	Sj23	48–59	30	[21]
	s.c	Sj PV1223	80	66	[58]
IL-4	s.c	Ad.pIXgp70	n.t	n.t	[28]
IL-18	i.m	Sj26GST	53.0–56.6	49.4	[59]
TSLP	s.c	SmESP	n.t	n.t	[26]
TSLP	s.c	rSG3PDH/PRX-MAP	33–66.9	69.3	[60]

^a Current vaccine candidates include Sj/SmTPI, Sj/Sm pmy, Sh28GST, Sm14, Sm-tsp-2, SjIR, Sj/Sm23 [3]; ^b Experimental data acquired in mice/rats unless specified; ^c Cocktail vaccination; Abbreviations: n.t: not tested; i.m: intramuscular; s.c: subcutaneous; TSLP: thymic stromal lymphoprotein; SG3PDH: glyceraldehyde 3-phosphate dehydrogenase; PRX-MAP: peroxiredoxin.